FFA
RNA

Farther Finance Advisors’s Atrium Therapeutics RNA Stock Holding History

Farther Finance Advisors’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62K Buy
+120
New +$1.57K ﹤0.01% 5231

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

Farther Finance Advisors's RNA Position: Q2 2026 in Review

Farther Finance Advisors opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 120 shares worth $1.62K. The stake represents ﹤0.01% of the portfolio and ranks #5231 among its holdings.

8 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Farther Finance Advisors held 120 shares of Atrium Therapeutics worth $1.62K as of Q2 2026.
  • Atrium Therapeutics was a new Farther Finance Advisors position in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5231 holding.
  • 8 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.